LICENSE AGREEMENT executed this 13 day of December, 2001. BETWEEN: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, (the "University") AND:License Agreement • December 16th, 2005 • Virexx Medical Corp • Biological products, (no disgnostic substances) • Alberta
NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the premises and of the mutual covenants herein set forth, the parties hereto have covenanted and agreed as follows:
Contract Research AgreementContract Research Agreement • December 16th, 2005 • Virexx Medical Corp • Biological products, (no disgnostic substances) • Alberta
This Contract Research Agreement (“Agreement”) is made effective this 15th day of November, 1998, by and between the Board of Governors of the University of Alberta on behalf of the Noujaim Institute for Pharmaceutical Oncology Research, (the “Institute”), Faculty for Pharmacy and Pharmaceutical Sciences, University of Alberta (the “University”), of the first part, and Noustar Technologies Inc., and Somagen Diagnostics Inc., collectively, of the second part, (“the Joint Venture”).
The Governors of the University of Alberta, a corporation duly organized and existing under the laws of the Province of Alberta and having its principal office at 222, 8625 - 112 Street, Edmonton, Alberta, T6G 2E1, Canada (hereinafter referred to as...Licensing Agreement • December 16th, 2005 • Virexx Medical Corp • Biological products, (no disgnostic substances) • Alberta
WHEREAS UA is the owner of certain PATENT RIGHTS (as later defined in this AGREEMENT) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 “A Method for Eliciting a Thl Specific Immune Response”(filed: September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed: June 7, 1995);
